Paredes-Aguilera R, Preston-Martin S, Douer D, Pogoda JM, Brenan B, López-Santiago N, Taboada-Meza C

Idioma: Español
Referencias bibliográficas: 65
Paginas: 83-93
Archivo PDF: 75.75 Kb.

FRAGMENTO

Introducción

Los estudios epidemiológicos han despertado interés sobre las variaciones en la incidencia y subtipos de las leucemias agudas (LAs) y los linfomas malignos, de acuerdo con las regiones geográficas y el origen étnico de las poblaciones estudiadas. Los resultados de series de grupos colaborativos y la experiencia de centros oncológicos aislados, han reportado una incidencia de leucemia aguda promielocítica (LAP) de 3 a 9 % en los subtipos de leucemia aguda mieloide en población pediátrica de origen caucásico. Esta es mucho menor que lo reportado en población mestiza en EUA, algunos países del sur de Europa y algunos países de América Latina (20-25%). Estos hallazgos sugieren una predisposición racial o geográfica a desarrollar LAP. De manera alternativa la distribución racial diferente, podría explicarse por factores nutricionales o ambientales con o sin una predisposición genética. El mismo fenómeno se ha observado en la enfermedad de Hodgkin, con inicio de la enfermedad en la etapa temprana de la vida y una mayor proporción de la variedad histológica de células mixtas en países en vías de desarrollo, en contraste con países desarrollados en donde la incidencia aumenta con la edad y se refiere un predominio de la variedad histológica de esclerosis nodular.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83.

2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92:2322-33.

3. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;87:308-13.

4. Douer D, Cozen W, Wang F, Chang E, Preston-Martin S, Levine AM. Descriptive epidemiology of acute promyelocytic leukemia (APL): report from the Cancer Registry for Los Angeles County, 1972-1995. Blood 1997;90(Suppl 1):310a (Abstract).

5. Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996;88:377.

6. Ruiz-Argüelles GJ. Promyelocytic leukemia in Mexican Mestizos. Blood 1997;89:348.

7. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997;11:1661-4.

8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol 1980;44:169-70 [Letter].

9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. A variant form of hypergranular promyelocytic leukemia (M3). Ann Intern Med 1980;92(2 Pt 1):261 [Letter].

10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.

11. Guthenson N, Cole P. Epidemiology of Hodgkin’s disease in the young. Int. J Cancer 1977;19:595-604.

12. Stiller CA, Parkin DM. International variations in the incidence of childhood lymphoma. Paediatr Perinat Epidemiol 1990;4:303-324.

13. Alexander FE, Williams J, McKinney PA et al. A specialist leukaemia/lymphoma registry in the UK. Part 2: Clustering of Hodgkin’s disease. Br J Cancer 1989;60:848-952.

14. Birch JM, Westerbeek R, Blair V, Eden OB, Kelsey A. Seasonal variations in onset of Hodgkin’s disease and acute lymphoblastic leukaemia in North West England. Med Pediatr Oncol 1997;29:364 (Abstract).

15. Guthenson N, Cole P. Childhood social environment and Hodgkin’s disease. N Engl J Med 1981;304:135-140.

16. Herbst H, Niedobitek G, Kneba M, et al. High incidence of Epstein-Barr virus genomes in Hodgkin’s disease. Am J Pathol 1990;137:13-18.

17. Wright CF, Reid AH, Tsai MM, et al. Detection of Epstein-Barr virus sequences in Hodgkin’s disease by the polymerase chain reaction. Am J Pathol; 138:393-398.

18. Weinreb M, Day PJR, Niggli F, et al. The role of Epstein-Barr virus in Hodgkin’s disease from different geographical areas. Arch Dis Child 1996;74:27-31.

19. Shankar AG, Ashley S, Radford M, Barrett A, Wright D, Pinkerton CR. Does histology influence outcome in childhood Hodgkin’s diease? Results from the United Kingdom Children’s Cancer Study Group. J Clin Oncol 1997;15:2622-2630.

20. Tubiana M, Henry Amar M, Carde P, et al. Towards comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group Controlled Clinical Trials 1964-1987. Blood 1989;73:47-56.

21. Sherins RJ, Devita VT. Effects of drug treatment for lymphoma on male reproductive capacity. Ann Intern Med 1973;79:216.

22. Sherins RJ, Olweny CLM, Ziegler JL. Gynecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkin’s disease. N Engl J Med 1978;299:12.

23. Whitehead E, Shalet SM, Morris-Jones PH. Gonadal function after combination chemotherapy for Hodgkin’s disease in childhood. Arch Dis Child 1982;57:287.

24. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic induced ovarian failure in women with Hodgkin’s disease. JAMA 1979;242:1877.

25. Morris-Jones PH, Beardwell CG, Deakin DP. Gonadal function after combination chemotherapy for Hodgkin’s disease. Arch Dis Child 1982;47:287.

26. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 1985;55:2364.

27. Bhatia S, Meadows AT, and et al. Family history of patients with breast cancer after treatment of Hodgkin’s disease in childhood (Letter). Lancet 1997;250:888.

28. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Eng J Med 1996;334:745-751.

29. Weiner MA, Leventhal BG, Brecher M, Marcus R, Cantor AB, et al. A randomised study of intensive MOPP-ABVD +/- low dose total nodal radiation therapy in the treatment of stages IIB, IIIA, III, IV Hodgkin’s disease in paediatric patients: a Pediatric Oncology Group Study (Abstract). Med Ped Onc 1993:21:60.

30. Hutchinson RJ, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin’s disease in children: results of CCG Phase III trial. J Clin Oncol 1998;16:897-906.

31. Behrebdt H, van Bunningen FM, and van Leeuwen EF. Treatment of Hodgkin’s disease in children with or without chemotherapy. Cancer 1987;59:1870.

32. Ekert H, Waters K. Results of treatment of 18 children with Hodgkin’s disease with MOPP chemotherapy as the only treatment modality. Med Ped Onc 1983;11:332.

33. Ekert H, Waters K, Smith PJ, Toogood I, et al. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin’s disease. J Clin Oncol 1988;6:1845.

34. Lobo-Sanahuja F, Garcia I, Barrantes JC, Barrantes M, Gonzalez M, Jimenez R. Pediatric Hodgkin’s disease in Costa Rica: twelve years’ experience of primary treatment by chemotherapy alone, without staging laparotomy. Med Ped Onc 1994;22:398-403.

35. Ortin TT, Shostak CA, Dfonaldson SS, et al. Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990;19:873.

36. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Ped Oncol 1996;27:74-78.

37. de Cunha MF, Meistrich ML, Fuller LM, et al. Recovery of spermatogenesis after treatment for Hodgkin’s disease: limiting dose of MOPP chemotherapy. J Clin Oncol 1984; 2:

38. Byrne J, Fears TR, Gail MH et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-793.

39. Bonadonna G, Valagussa P, and Santoro A. Alternating non cross resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 1986;104:739.

40. van den Berg, Stuve W, Behrendt H. Treatment of Hodgkin’s disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy. Med Ped Oncol 1997. p. 23-27

41. Vecchi V, Pileri S, Burnelli R, and et al. Treatment of pediatric Hodgkin’s disease tailored to stage, mediastinal mass and age. Cancer 1993;72:2049.

42. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol 1996;14:1421-1430.

43. Hickish T, Roldan A, Cunningham D et al. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer 1993; 68:599-604.

44. — Romero F, Paredes R. Definición de riesgo en leucemia aguda, de acuerdo a la clasificación. En: actualización en leucemias. Primera ed. México: Editorial Panamericana; 1996. p. 41-49.

45. — Mastrangelo R, Poplack D, Bleyer A, et al. Report and recomendations of the Rome Workshop Concerning Poor-Prognosis Acute Lymphoblastic Leukemia in Children: biologic bases for stanging, stratification and treatment. Med and Pediatr Oncol 1986;14:191-4.

46. — Crist W, Pullen J, Boyett J, et al. Clinical and biological features predict a poor prognosis in acute lymphoblastic leukemias in infants: a Pediatric Oncology Group Study. Blood 1986;67:135-140.

47. — Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the Multicenter Trial ALL-BFM 86. Blood 1994;84:3122-3133.

48. — Hence G, Fengler R, Hartman R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A Relapse Study of the BFM Group. Blood 1991;78:1166-1172.

49. — Lelleyman JS, Hann IM, Stevens RF, et al. Cytomorphology of childhood lymphoblastic leukemia: a prospective study of 2000 patients. Br J Haematol 1992;81:52-57.

50. — Pui CH, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991;78:1327-1337.

51. — Kaspers GJL, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995;85:751-756.

52. — Crist WM, Carroll AJ, Shusters JJ, et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group Study. Blood 1990;76:117-122.

53. — Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the german Italian multicenter therapy trials. Blood 1997;90:571-577.

54. — Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease- free survival and late recurrence of childhood acute lymphobastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 1989; 7:1807-1815.

55. — Gaynon PS, Bleyer A, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med and Ped oncol 1990;18:273-279.

56. — Rivera G, Raimondi S, Handcock ML, et al. Improvement outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 199;337:61-66.

57. — Lennard L, Lelleyman JS. Variable mercaptoppurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-18823.

58. Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12: 339-350.

59. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12: 327-338.

60. Ceci A, De Terlizi M, Colella R, Loiacono G, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X’83 Study. Med Pediatr Oncol 1993; 21: 259-264.

61. Gadner H, Heitger A, Grois N et al. Treatment strategy for disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994; 23: 72 – 80.

62. Sullivan JL, Bruce AW. Lymphohistiocytic disorders. In: Nathan D, Stuart H, editors. Nathan and Oski?s Hematology of Infancy and childhood. 5th ed. Philadelphia, PA, USA: WS Saunders Co., 1998. p. 1359 -1380.

63. Ladish S, Gadner H, Arico M, et al. LCH-1: A randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994;23:107-110.

64. Culic S, Jakobson A, Culic V, Kuzmic I. Etoposide as the basic and interferon-a as the maintenance therapy for Langerhans cell histiocytosis: A RTC. Pediatr Hematol Oncol. 2001;18: 291-294.

65. Watts J, Files B. Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxya-denosine. Pediatr Hematol Oncol 2001;18:199 -204.